Cross-talk between the thyroid and liver:A new target for nonalcoholic fatty liver disease treatment

被引:3
|
作者
Yue-Ye Huang [1 ]
Aaron M Gusdon [2 ]
Shen Qu [1 ,3 ]
机构
[1] Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, School of Medicine, Tongji University
[2] Department of Neurology and Neuroscience,Weill Cornell Medical College, New York, NY 10065, United States
[3] Department of Endocrinology and Metabolism, Nanjing Medical University
关键词
Thyroid hormone; Thyroid hormone receptor; Nonalcoholic fatty liver disease; Obesity;
D O I
暂无
中图分类号
R575.5 [肝代谢障碍];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic fatty liver disease(NAFLD)has been recognized as the most common liver metabolic disease,and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now.Thyroid hormone(TH)and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver.It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions.TRβ1 is predominantly expressed in the brain and adipose tissue and TRβ2 is the major isoform in the liver,kidney and fat.They have different functions and play important roles in lipid metabolism.Recently,there are many studies on the treatment of NAFLD with TH and its analogues.We review here that thyroid hormone and TR are a potential target for pharmacologic treatments.Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues.
引用
收藏
页码:8238 / 8246
页数:9
相关论文
共 50 条
  • [31] Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease
    Sun, Dan-Qin
    Wu, Sheng-Jie
    Liu, Wen-Yue
    Lu, Qian-Di
    Zhu, Gui-Qi
    Shi, Ke-Qing
    Braddock, Martin
    Song, Dan
    Zheng, Ming-Hua
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (03) : 375 - 387
  • [32] Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Hung, Chun Kit
    Bodenheimer, Henry C., Jr.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 175 - +
  • [33] Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Golabi, Pegah
    Bush, Haley
    Younossi, Zobair M.
    CLINICS IN LIVER DISEASE, 2017, 21 (04) : 739 - 753
  • [34] Nonalcoholic Fatty Liver Disease After Liver Transplantation for Cryptogenic Cirrhosis or Nonalcoholic Fatty Liver Disease
    Yalamanchili, Kanthi
    Saadeh, Sherif
    Klintmalm, Goeran B.
    Jennings, Linda W.
    Davis, Gary L.
    LIVER TRANSPLANTATION, 2010, 16 (04) : 431 - 439
  • [35] Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
    Abenavoli, Ludovico
    Falalyeyeva, Tetyana
    Boccuto, Luigi
    Tsyryuk, Olena
    Kobyliak, Nazarii
    PHARMACEUTICALS, 2018, 11 (04)
  • [36] Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease
    Toshikuni, Nobuyuki
    Tsutsumi, Mikihiro
    Arisawa, Tomiyasu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8393 - 8406
  • [37] Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease
    Nobuyuki Toshikuni
    Mikihiro Tsutsumi
    Tomiyasu Arisawa
    World Journal of Gastroenterology, 2014, (26) : 8393 - 8406
  • [38] Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-α
    Tobin, KAR
    Steineger, HH
    Alberti, S
    Spydevold, O
    Auwerx, J
    Gustafsson, JÅ
    Nebb, HI
    MOLECULAR ENDOCRINOLOGY, 2000, 14 (05) : 741 - 752
  • [39] Thyroid hormones and nonalcoholic fatty liver disease in diabetes patients
    Pavlicek, Vojtech
    DIABETOLOGIE, 2022, 18 (06): : 752 - 753
  • [40] Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese
    Xu, Chengfu
    Xu, Lei
    Yu, Chaohui
    Miao, Min
    Li, Youming
    CLINICAL ENDOCRINOLOGY, 2011, 75 (02) : 240 - 246